Table 2 Eligibility for E1594 and SWOG9509
From: Eligibility of patients with advanced non-small cell lung cancer for phase III chemotherapy trials
Prospective Data N = 100 (%) | Retrospective Data N = 85 (%) | Entire Cohort N = 185 (%) | |
|---|---|---|---|
E1594: | |||
Ineligible | 61 (61%) | 60 (70.5%) | 121 (65%) |
Eligible | 39 (39%) | 22 (26%) | 61 (33%) |
Not assessable | 0 (0%) | 3 (3.5%) | 3 (2%) |
SWOG 9509 | |||
Ineligible | 66 (66%) | 66 (78%) | 132 (71%) |
Eligible | 34 (34%) | 16 (19%) | 50 (27%) |
Not assessable | 0 (0%) | 3 (3.5%) | 3 (2%) |